ICMJE DISCLOSURE FORM

Date	e: 16. september 2023		
You	r name: Anne Gerdes		
Mar	nuscript title: AI-etik i sundh	nedsvæsenet - i spændingsfe	eltet mellem forventningspres, behovet for
patie	entinddragelse og kliniske don	næneeksperter	
Mar	nuscript number (if known)):	
are re third comr list a The f	elated to the content of you parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is no oort for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this		
	item.		Clial TAD in last south add autor gove
Time	e frame: past 36 months		Click TAB in last row to add extra rows
111118	e frame. past 30 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Non	
3 Royalties or licenses ☑ None			

4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Non	
6	Payment for expert	None Non	
	testimony		
7	Support for attending	None Non	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data		
	Safety Monitoring Board	ZI NOTIC	
	or Advisory Board		
10	Loadorchin or fiduciary	SZ Name	
10	Leadership or fiduciary role in other board,	⊠ None	
	society, committee or advocacy group, paid or unpaid		
11	11 Stock or stock options None		
	Stock of Stock options	M NOTE	
12 Receipt of equipment, None		M None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
12	Other financial as non	SZ Name	
13	Other financial or non- financial interests	⊠ None	

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal



ICMJE DISCLOSURE FORM

Dat	e: 16. september 2023		
You	Ir name: Iben Fasterhold	t	
			eltet mellem forventningspres, behovet for agelse og kliniske domæneeksperter
Mar	nuscript number (if known):	
are re third comr list a	elated to the content of yo parties whose interests m mitment to transparency a relationship/activity/intere	our manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	
	following questions apply to uscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
perta	ains to the epidemiology of	f hypertension, you should	defined broadly. For example, if your manuscript dideclare all relationships with manufacturers of ot mentioned in the manuscript.
	em #1 below, report all sup r items, the time frame for		d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None	
	2023	The EDiHTA project (Co-	7,986 millions € (771.349€ for OUH), The European
	2023	applicant) MAS-Al research stays (Principal Applicant)	Commission 170K DKK, Odense University Hospital -

	2022	LiverPRO (Co-applicant)	500K DKK, Novo Nordisk BETA Health grant
	2022	Greener transport of	220K DKK, Odense University Hospital Innovation
		medicines and blood	grant
		samples with	
		HealthDrones (Co-	
	0000	applicant)	240// DW/ 11 1 1 2 3 4 11 1 1 2 3
	2022	Follow-up study of	310K DKK, Høgskulan på Vestlandet + Steno Diabetes
		telemedicine monitoring of diabetic foot ulcers	Center Odense
		(Principal-applicant)	
	2021	Assessing the value of Al	356K DKK, the Region of Southern Denmark.
		technologies – which	
		should we invest in?	
		(Principal Applicant)	
	2021	The Canadian workshop	9,750 CAD, TRANSFORM-HF ISI Collaboration Starter
		to Validate MAS-AI (Co-	Grants Program
	2021	applicant) "Patient first" when	100K DKK Odonos University Heavital Impovetion
	2021	assessing AI - doing co-	100K DKK, Odense University Hospital Innovation grant
		creation in MAS-AI (Co-	grant
		applicant)	
	D 11'		
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
ľ	Consuming roos	Z Nonc	
5	Payment or honoraria for	□ None	
	lectures, presentations, speakers bureaus,	Research training course	Content: Introduction to Mini-HTA.
	manuscript writing or	for specialist doctors in	
	educational events	Region Zealand.	
6	Payment for expert	None Non	
	testimony		
7	Support for attending	□ None	
	meetings and/or travel	ESMDM (Society for	Funding from: Toronto Health Economics and
		Medical Decision	Technology Assessment Collaborative. University
		Making), Berlin,	Health Network (UHN)
		Germany, May 2023	For the Company Tours I I I I I I
		CADTH Symposium,	Funding from: Toronto Health Economics and
		Ottawa, Canada, May 2023	Technology Assessment Collaborative. University Health Network (UHN)
		Health Technology	Funding from: Odense University Hospital
		Assessment	- and ing it of it. Odoriso of it of sity Hospital
		International (HTAi),	
		Utrecht, Netherlands,	
		June 2022	
8	Patents planned, issued or	None Non	
١	· ·	M INOLIC	T
	pending		

9	Participation on a Data Safety Monitoring Board	⊠ None	
	or Advisory Board		
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None Non	
		1	
13	Other financial or non-	None Non	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

ICMJE DISCLOSURE FORM

Date	e: 22. september 2023		
You	r name: Benjamin S. B.F	Rasmussen	
Manuscr	ript title: AI-etik i sundhedsvæsenet - i spæ	ndingsfeltet mellem forventningspres	behovet for patientinddragelse og kliniske domæneeksperter
Mar	nuscript number (if known):	
are re third comn list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit cent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. Des/activities/interests as they relate to the current
	uscript only.	·	, , , , , , , , , , , , , , , , , , , ,
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
other	items, the time frame for	disclosure is the past so i	HOHEHS.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	
	TCIIII		Click TAD in last value to add out value
Click TAB in last row to add extra rows			
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests	4	Consulting fees	⊠ None	
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
manuscript writing or educational events 6	5	lectures, presentations, speakers bureaus, manuscript writing or	⊠ None	
6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-				
testimony Support for attending meetings and/or travel Support for a fo				
testimony Support for attending meetings and/or travel Support for attending for a f	6	Payment for expert	₩ None	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-			≥ None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services None				
Receipt of equipment, materials, drugs, medical writing, gifts or other services None	7	Support for attending	S No.	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-	′		⊠ None	
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-	0	Datants planned issued or	S No.	
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-	٥	-	⊠ None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		perianig		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	9		⊠ None	
role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Stock or stock options None				
role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options Stock or stock options None				
society, committee or advocacy group, paid or unpaid 11 Stock or stock options Stock or stock options None	10		⊠ None	
advocacy group, paid or unpaid 11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None		society, committee or advocacy group, paid or		
11 Stock or stock options None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-	11	11 Charles on short and state of the state o		
materials, drugs, medical writing, gifts or other services 13 Other financial or non-	11	Stock of Stock options	△ None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non-				
materials, drugs, medical writing, gifts or other services 13 Other financial or non-	12	43 Provint of aminus at 17 at		
writing, gifts or other services 13 Other financial or non- None	12	materials, drugs, medical writing, gifts or other	⊠ None	
13 Other financial or non-				
	13		⊠ None	
			≥ HOIL	

Please place an "X" next to the following statement to indicate your agreement:

 $oxed{\boxtimes}$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal